ALNY
Alnylam Pharmaceuticals, Inc.NASDAQHealthcare$318.85-3.01%ClosedMarket Cap: $42.29B
As of 2026-04-06
Valuation
P/E (TTM)
134.78
PEG
0.63
P/B
53.43
P/S
11.39
EV/EBITDA
88.66
DCF Value
$-1,681.71
FCF Yield
1.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
81.7%
Operating Margin
13.5%
Net Margin
8.4%
ROE
90.3%
ROA
6.3%
ROIC
13.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.10B | 75.6% | $131.7M | $186.4M | $1.37 | — |
| FY 2025 | $3.71B | 81.8% | $501.6M | $313.7M | $2.33 | — |
| Q3 2025 | $1.25B | 84.2% | $368.0M | $251.1M | $1.84 | — |
| Q2 2025 | $773.7M | 81.5% | $-16.2M | $-66.3M | $-0.51 | — |
| Q1 2025 | $594.2M | 88.0% | $18.1M | $-57.5M | $-0.44 | — |
| Q4 2024 | $593.2M | 82.7% | $-105.2M | $-83.8M | $-0.65 | — |
| FY 2024 | $2.25B | 85.6% | $-176.9M | $-278.2M | $-2.18 | — |
| Q3 2024 | $500.9M | 82.9% | $-76.9M | $-111.6M | $-0.87 | — |
| Q2 2024 | $659.8M | 89.6% | $48.6M | $-16.9M | $-0.13 | — |
| Q1 2024 | $494.3M | 86.7% | $-43.4M | $-65.9M | $-0.52 | — |
| Q4 2023 | $439.7M | 80.5% | $-116.4M | $-137.9M | $-1.10 | — |
| FY 2023 | $1.83B | 83.0% | $-282.2M | $-440.2M | $-3.52 | — |